Technology

IGM Biosciences

$97.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.68 (+2.84%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell IGMS and other stocks, options, and ETFs commission-free!

About IGMS

IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firms product pipe line includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies; IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies; and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA. The listed name for IGMS is IGM Biosciences, Inc. Common Stock.

CEO
Fred M. Schwarzer
Employees
64
Headquarters
Mountain View, California
Founded
2010
Market Cap
2.89B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
193.32K
High Today
$99.55
Low Today
$93.10
Open Price
$93.10
Volume
142.93K
52 Week High
$133.00
52 Week Low
$27.55

Collections

IGMS Earnings

-$2.41
-$1.61
-$0.80
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 25, Pre-Market

You May Also Like

BKRKY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure